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Abstract
Introduction: Acute kidney injury (AKI) is commonly observed in the intensive care unit (ICU), where it can be
caused by a variety of factors. The objective of this study was to evaluate the prognostic value of urinary
angiotensinogen, a candidate prognostic AKI biomarker identified in post-cardiac surgery patients, in this
heterogeneous population.
Methods: Urinary angiotensinogen was measured by ELISA and corrected for urine creatinine in 45 patients who
developed AKI in the ICU. Patients were grouped by AKI etiology, and the angiotensinogen-to-creatinine ratio (uAnCR)
was compared among the groups using the Kruskal-Wallis test. The ability of uAnCR to predict the following endpoints
was tested using the area under the ROC curve (AUC): the need for renal replacement therapy (RRT) or death, increased
length of stay (defined as hospital discharge > 7 days or death ≤ 7 days from sample collection), and worsening AKI
(defined as an increase in serum creatinine > 0.3 mg/dL after sample collection or RRT).
Results: uAnCR was significantly elevated in patients who met the composite outcome RRT or death (89.4 vs
25.4 ng/mg; P = 0.01), and it was a strong predictor of this outcome (AUC = 0.73). Patients with uAnCR values
above the median for the cohort (55.21 ng/mg) had increased length of stay compared to patients with uAnCR ≤
55.21 ng/mg (22 days vs 7 days after sample collection; P = 0.01). uAnCR was predictive of the outcome increased
length of stay (AUC = 0.77). uAnCR was also a strong predictor of worsening of AKI (AUC = 0.77). The uAnCR of
patients with pre-renal AKI was lower compared to patients with AKI of other causes (median uAnCR 11.3 vs
80.2 ng/mg; P = 0.02).
Conclusions: Elevated urinary angiotensinogen is associated with adverse events in AKI patients in the ICU. It
could be used to identify high risk patients who would benefit from timely intervention that could improve their
outcomes.
Introduction
Acute kidney injury (AKI) is reflected by an increase in
serum creatinine (sCr) or a decrease in urine output, the
magnitude of which is used to assess the severity of renal
injury using the risk, injury, failure, loss, end-stage renal
failure (RIFLE) or Acute Kidney Injury Network (AKIN)
staging systems [1,2]. A patient’s risk of both short- and
long-term adverse outcomes is correlated with the severity
of AKI as determined using these staging systems [3-7].
For example, a large retrospective cohort study of a criti-
cally ill population reported that the odds ratio (OR) for
in-hospital mortality increased from 2.07 in AKIN stage 1
patients to 2.99 in AKIN stage 3 patients [8]. However,
because sCr does not reach steady state until after an
acute reduction in glomerular filtration rate (GFR) has
occurred, the severity of AKI can only be definitively
determined late in the disease. The conceptual framework
for understanding AKI proposed by Murray et al. under-
scores the importance of progression from the early stages
of AKI, in which an at-risk patient experiences renal
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injury, to later stages of the disease, which include
decreased GFR, renal failure, and death [9]. Similarly, the
2012 Kidney Disease: Improving Global Outcomes
(KDIGO) Clinical Practice Guideline for AKI highlights
the need for accurate assessment of a patient’s risk of
adverse outcomes, notably progression to a more severe
stage of AKI after renal injury has occurred [10].
Unfortunately, it is difficult to determine if a patient
with a small increase in sCr will worsen, improve, or stay
the same. Furthermore, it is not possible to differentiate
mild from severe AKI at an early time point using conven-
tional diagnostic criteria. Biomarkers that reflect the mag-
nitude of tubular injury at the time they are collected
could serve this function. Novel AKI biomarkers such as
kidney injury molecule 1 (KIM-1), neutrophil gelatinase
associated lipocalin (NGAL), IL-18, and Cystatin C can
diagnose AKI prior to detectable changes in sCr [11-19].
However, two recent studies have reported unadjusted
area under the curve (AUC) values for prediction of wor-
sening AKI between 0.58 and 0.71, suggesting that diag-
nostic AKI biomarkers are of lesser predictive value
among patients who already have established AKI [20,21].
Therefore, prognostic biomarkers that predict outcomes
in patients with established AKI are needed.
We recently identified urinary angiotensinogen as a
novel prognostic biomarker, capable of predicting adverse
outcomes including worsening of AKI and the need for
renal replacement therapy after cardiac surgery [22]. How-
ever, AKI is a heterogenous syndrome that can be caused
by many precipitating factors other than surgery, and it is
common among critically ill patients. Because the prog-
nostic predictive power of an AKI biomarker may differ
with the pathobiology underlying the etiology it is neces-
sary to determine if the prognostic predictive value of
angiotensinogen is generalizable to AKI of other etiologies.
Therefore, in the current study we investigated the prog-
nostic predictive power of angiotensinogen in a cohort of
critically ill, non-surgical patients in the ICU, who devel-
oped AKI.
Materials and methods
Patients and urine samples
All patients (n = 45) had been admitted to the ICU at the
Medical University of South Carolina (MUSC) Hospital.
Patients either had AKI at ICU admission or developed
AKI during their stay in the ICU. AKI was defined accord-
ing to the AKIN criteria [2]. When possible, baseline sCr
was defined as the most recent (within 1 month) value
prior to the AKI episode. When antecedent sCr values
were not available, the lowest sCr observed during the
patient’s hospital stay was used as the baseline. Informed
consent was obtained from the patients or their next of
kin prior to urine sample collection, in accordance with
the MUSC Institutional Review Board approved protocols.
The only exclusion criteria were initiation of renal replace-
ment therapy (RRT) prior to sample collection and
non-consent. Patients for this study were selected retro-
spectively to perform a case-control study of ICU patients
diagnosed with AKI at the time of urine sample collection.
The primary outcome was the need for renal replacement
therapy or death, and patients who had AKI at the time of
sample collection but did not meet the primary outcome
were selected as controls. Decisions about initiating RRT
were made by the clinical attending physician. Samples
were collected at the time that the diagnosis of AKI was
made. If patients had AKI on admission, samples were col-
lected immediately after admission. Urine samples were
processed according to a standard operating procedure.
They were treated with a protease inhibitor cocktail
(Roche, Indianopolis, IN), Mini, ethylenediaminetetraace-
tic acid (EDTA)-free), centrifuged for 10 minutes at 1,000
× g and the supernatant was aspirated and stored at -80°C
until the time of use. Clinical data were obtained by retro-
spective chart review. Etiology of AKI was determined and
patients were assigned to one of four categories: pre-renal,
ischemic Acute tubular necrosis (ATN), sepsis-associated
AKI, and other. Pre-renal AKI was defined as an episode
of AKI in the setting of hypotension or hypovolemia in
which the patient’s sCr decreased to < 150% of baseline
within 48 hours after diagnosis. Ischemic ATN was
defined as severe, prolonged AKI following any event that
compromises renal blood flow or oxygen delivery. The
specific events observed in our cohort included ruptured
abdominal aortic aneurysm, cardiogenic shock, and
exacerbation of congestive heart failure. Patients for whom
the etiology could not be determined or was multifactorial
were included in the category, other.
Determination of urinary angiotensinogen-to-creatinine
ratio
Urinary angiotensinogen was measured using the Human
Total Angiotensinogen Assay Kit (Immuno-Biological
Laboratories Co., Ltd., IBL-America, Minneapolis, MN,
USA), a solid-phase sandwich ELISA, according to the
manufacturer’s protocol. Urine creatinine was measured
using the Jaffe assay and used to correct the urine angio-
tensinogen concentration as was done in the previous ana-
lysis of angiotensinogen as a biomarker after cardiac
surgery. Values were reported as the ratio of angiotensino-
gen in ng/ml to creatinine in mg/ml (uAnCR, ng/mg). The
AUC value was higher for the primary outcome when
creatinine corrected values were used (not shown).
Outcomes
The primary outcome was the composite outcome of
the need for RRT or death. Increased length of hospital
stay was defined as hospital discharge > 7 days from the
day of sample collection or death ≤ 7 days from sample
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collection. Worsening of AKI was defined as an addi-
tional increase in sCr > 0.3 mg/dL from the sCr at the
time of the urine sample collection or the initiation of
RRT.
Statistical analysis
The Kruskal-Wallis test and post hoc Dunn’s test were
used to compare the uAnCR values of patients grouped by
AKI etiology. The Mann-Whitney U-test was used when
only two groups were compared. Other continuous vari-
ables were compared using the t-test or Mann-Whitney
U-test. Categorical variables were compared using the chi
squared (c2) or Fisher’s exact tests. Logistic regression was
used to determine the multiplicative OR for a one SD
increase in uAnCR. However, because uAnCR was not
normally distributed, it was first log10 transformed for this
analysis. Receiver operator characteristic (ROC) curves
were used to test the ability of uAnCR to predict out-
comes, and the AUC was used as an estimate of an overall
accuracy of the biomarker. The ROC curve was considered
statistically significant if the AUC differed from 0.5, as
determined by the z-test. Optimal cutoffs were determined
by selecting the data point that minimized the geometric
distance from 100% sensitivity and 100% specificity on the
ROC curve. Additional cutoffs were determined by select-
ing the points on the ROC at which the positive and nega-
tive likelihood ratios were maximized and minimized,
respectively. The Spearman’s correlation coefficient was
used to determine the correlation between uAnCR and
length of hospital stay. Kaplan-Meier curves were used to
visualize the relationship between uAnCR and length of
hospital stay. Patients who died were censored. The log
rank test was used to compare the curves. Cox regression
was used to calculate the proportional hazard ratio for
time to discharge comparing patients with high and low
uAnCR (defined as > the median or ≤ the median of the
cohort). The Cox proportional hazard model included
both the patient’s uAnCR and AKIN stage at collection.
Results
Patient characteristics
Urine samples were obtained from patients with AKI in
the ICU (n = 45). At the time of sample collection, five
patients were classified as AKIN stage 3, 12 patients as
AKIN stage 2, and 28 patients as AKIN stage 1. Baseline
patient characteristics are described in detail in Table 1. In
approximately one-third of patients, the etiology of AKI
could not be determined or was multifactorial (n = 16).
Sepsis-associated AKI was the most common established
etiology (n = 15), followed by pre-renal AKI (n = 8), and
ischemic acute tubular necrosis (n = 5). Twenty-three
patients met the primary outcome, the need for renal
replacement therapy (RRT) or death, of which five patients
required RRT but survived, and eleven patients died but
did not receive RRT. Pre-renal AKI was significantly more
common among the patients who did not meet this out-
come (P = 0.01). There were no statistically significant dif-
ferences between the group of patients who required RRT
or died compared to those who did not, with respect to
age, race, gender, the day of sample collection (defined as
days after the date that AKI criteria were met), sCr at
baseline, sCr at the time of sample collection, or the per-
cent change in sCr from baseline at the time of sample
collection. However, patients who met the primary out-
come had lower rates of hypertension, diabetes mellitus,
and the use of angiotensin converting enzyme inhibitors
or angiotensin receptor blockers.
Angiotensinogen predicts RRT or death
Urinary angiotensinogen was elevated in the group of
patients who met the primary outcome of RRT or death
(median uAnCR = 89.4 ng/mg, IQR 35.9 to 335.6 ng/mg)
compared to the group who did not (median uAnCR =
25.4 ng/mg, IQR 5.8 to 120.4 ng/mg) (Figure 1A). Elevated
uAnCR was associated with an increased risk of meeting
this outcome. The multiplicative OR for a one SD increase
in a patient’s uAnCR was 2.61 (95% CI 1.23, 5.53). The
ROC curve for this outcome had an AUC of 0.73 (P =
0.01) (Figure 1B). The optimal cutoff was 34.76 ng/mg, at
which the test had a sensitivity and specificity of 78.3%
and 54.6%, respectively. The cutoff at which the test had
the highest positive likelihood ratio (LR+ = 9.6) was 230.0
ng/mg. Eleven of the forty-five AKI patients had uAnCR
values greater than 230.0 ng/mg; ten of these met the out-
come. At this cutoff, the sensitivity and specificity of the
prediction of RRT or death were 43.5% and 95.5%, respec-
tively, and the positive predictive value was 90.9%.
Similarly, the lowest negative likelihood ratio of the test
was achieved at a cutoff of 7.58 ng/mg (LR- = 0.14). Eight
patients had uAnCR values ≤ 7.58 ng/mg; seven of these
did not meet the outcome. The test had a sensitivity and
specificity of 95.7% and 31.8%, respectively at this cutoff.
Length of hospital stay
Among patients who survived to discharge (n = 26),
uAnCR was correlated with days to hospital discharge (r =
0.57, P = 0.002). Patients who had high uAnCR values
(defined as > 55.21 ng/mg, the median value) had an
increased (LOS) compared to patients who had low
uAnCR (≤ 55.21 ng/mg). The median LOS (defined as
days after the time of sample collection) for these groups
was 22 days and 7 days, respectively (P = 0.01) (Figure 2A),
and the AKIN stage-adjusted hazard ratio for discharge
was 0.367 (95% CI 0.17, 0.91) for patients with high
uAnCR compared to those with low uAnCR, indicating
that uAnCR affects LOS independently of changes in sCr.
Elevated uAnCR was strongly associated with an increased
risk of the composite outcome discharge > 7 days from the
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Table 1 Characteristics of ICU patients used to verify the prognostic predictive power of urinary angiotensinogen as
an acute kidney injury biomarker
No RRT and Survival RRT or Death P-value
Number of patients 22 23
Age, yrsa 62.9 ± 16.1 54.4 ± 17.6 0.1
Caucasian, % (n) 64 (14) 65 (15) 0.84
Male, % (n) 55 (12) 65 (15) 0.67
AKI etiology, n (%)
Sepsis 23 (5) 43 (10) 0.25
Pre-renal 32 (7) 4 (1) 0.01
Ischemic ATN 9 (2) 13 (3) 1
Other 36 (8) 39 (9) 0.91
Serum creatinine (sCr), mg/dL
Baseline sCrb 1.15 (0.8, 1.6) 1.1 (1.0, 1.5) 0.98
sCr at collectiona 2.1 ± 0.8 2.5 ± 0.8 0.06
Change in sCrb, % 150 (130 to 189) 200 (150 to 257) 0.07
AKIN stage at collection 0.14
Stage 1 17 11
Stage 2 4 8
Stage 3 1 4
Outcomes, % patients (n)
RRT 0 52 (12) < 0.001
Death 0 78 (18) < 0.001
Other variables
MAP on day of collectionb 74.9 (70.4 to 86.8) 68.6 (64.5 to 84.1) 0.08
History of HTN, % patients (n) 91 (20) 48 (11) 0.005
History of diabetes mellitus, % patients (n) 55 (12) 22 (5) 0.05
History of ACE inhibitor or ARB use, % patients (n) 48 (12) 17 (4) 0.03
aMean ± SD; bmedian and IQR; categorical data are shown as percentage and number. P-values are shown for the c2 or Fisher exact test, as appropriate. RRT,
renal replacement therapy; AKI, acute kidney injury; ATN, Acute tubular necrosis}; AKIN, Acute Kidney Injury Network; MAP, Mean arterial pressure}; HTN,
Hypertension}; ARB, Angiotensin receptor blocker}.
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Figure 1 The urinary angiotensinogen-to-creatinine ratio in patients who met the outcome renal replacement therapy or death
compared to patients who did not. (A) Box and whisker plots show the median and interquartile range. Error bars represent the 5th and 95th
percentiles. (B) A receiver operator characteristic curve was performed to evaluate the ability of the angiotensinogen-to-creatinine ratio (uAnCR)
to predict the outcome renal replacement therapy (RRT) or death. The area under the curve (AUC) was 0.73.
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time of sample collection or death ≤ 7 days from collec-
tion. The multiplicative OR for one SD increase in uAnCR
was 3.31 (95% CI 1.36, 8.04). ROC curve analysis demon-
strated that uAnCR was a strong predictor of this outcome
(AUC = 0.77) (Figure 2B). At the optimal cutoff, 59.61 ng/
mg, the sensitivity and specificity of the prediction of pro-
longed hospital stay was 60.6% and 83.3%, respectively.
The cutoff at which the test had the highest positive likeli-
hood ratio (LR+ = 5.5) was 123.5 ng/mg. Sixteen patients
were above this cutoff, of which fifteen met the outcome.
At this cutoff, the sensitivity and specificity of the test was
43.5% and 95.5%, respectively. Similarly, the lowest nega-
tive likelihood ratio of the test was achieved at a cutoff of
3.31 ng/mg (LR- = 0.12). Four patients had uAnCR values
≤ 3.31 ng/mg; three of these did not meet the outcome.
The test had a sensitivity and specificity of 97.1% and
25.0%, respectively at this cutoff.
Worsening of AKI
Elevated uAnCR was associated with an increased risk of
worsening AKI after sample collection (Figure 3). The
ROC curve for this outcome had an AUC of 0.77. At the
optimal cutoff, 34.76 ng/mg, the sensitivity and specificity
was 87.0% and 63.6%, respectively. At the cutoff with the
maximum LR+, 230.0 ng/mg (LR+ = 4.31), the sensitivity








































Figure 2 Urinary angiotensinogen-to-creatinine ratio and length of stay. (A) Patients were stratified into groups by urinary
angiotensinogen-to-creatinine ratio (uAnCR). Patients with uAnCR > the median for the cohort were classified as high (red line), whereas
patients with uAnCR ≤ the median were classified as low (black line). Patients who died were censored. The median times to discharge (defined
as days after sample collection) were 22 and 7 days for the high and low uAnCR groups, respectively. (B) Receiver operator characteristic (ROC)
curve analysis was performed to evaluate the ability of uAnCR to predict the composite outcome discharge > 7 days after sample collection or
















Figure 3 The urinary angiotensinogen-to-creatinine ratio as a
predictor of the outcome worsening of acute kidney injury.
Receiver operator characteristic curve for the composite outcome
worsening of acute kidney injury (defined as an increase in serum
creatinine > 0.3 mg/dL after the time of sample collection or renal
replacement therapy). AUC, area under the curve.
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cutoff with the lowest LR-, 21.24 ng/mg (LR- = 0.073), the
sensitivity and specificity was 95.7% and 59.1%. Eleven
patients had uAnCR values above the cutoff of maximal
LR+; ten of these met the outcome of worsening of AKI.
Fourteen patients had uAnCR values below the threshold
of minimal LR-; only one of these met the outcome.
Urinary angiotensinogen by AKI etiology
The uAnCR differed statistically with the underlying etiol-
ogy of AKI. Patients were categorized into the dichoto-
mous groups of pre-renal AKI and AKI of other etiologies
(Figure 4). The median uAnCR for patients with pre-renal
AKI (n = 8) was 11.3 (IQR 5.2 to 61.5), while the median
for patients with AKI not classified as pre-renal etiology
(n = 37) was 80.2 ng/mg (IQR 22.7 to 259.2). There was a
statistically significant difference between the uAnCR
values of this group compared to the group of patients
with pre-renal AKI (P = 0.03). The values for the four
separate etiologic groups are shown in Additional file 1.
Patients with AKI secondary to ischemic ATN had the
highest median uAnCR (260.2 ng/mg, IQR 69.6 to 1213.2),
followed by patients with AKI due to other or unknown
causes, including multifactorial etiology (90.6 ng/mg, IQR
12.1 to 251.5), patients with sepsis-associated AKI (48.1
ng/mg, IQR 23.5 to 222.4), and patients with pre-renal
AKI (11.3, IQR 5.2 to 61.5).
Discussion
Urinary angiotensinogen has been previously identified as
a prognostic biomarker of AKI after cardiac surgery [22].
However, at the time of its discovery it was unclear if its
prognostic significance was generalizable to AKI secondary
to causes other than cardiac surgery. In the present study,
we measured urinary angiotensinogen in ICU patients
who developed AKI secondary to diverse etiologies.
We found that elevated urinary angiotensinogen was asso-
ciated with an increased risk of RRT or death, longer time
to hospital discharge, and worsening of AKI after the time
of sample collection, and that angiotensinogen was a
strong predictor of these outcomes using ROC curve ana-
lysis (Table 2). Urinary angiotensinogen was statistically
decreased in patients with pre-renal AKI compared to
those with AKI of other etiologies, and the pre-renal AKI
was more common in the group of patients who did not
die or require RRT. It is important to distinguish between
pre-renal AKI and AKI of other causes since pre-renal
AKI typically is transient and resolves with fluid resuscita-
tion, whereas other more severe forms do not. Pre-renal
AKI is classically differentiated from AKI of other etiolo-
gies by fractional excretion of sodium (FeNa) < 1% or frac-
tional excretion of urea (FeUrea) < 35% [23-25]. However,
FeNa can be confounded by diuretic use and is altered in
the setting of sepsis, whereas FeUrea decreases with age,
and a multicenter trial reported that it was not diagnostic
of transient AKI [24-26]. Better biomarkers of pre-renal
AKI are clearly needed. In a recent study that used a defi-
nition of pre-renal azotemia, which was very similar to
ours, cystatin C, NGAL, IL-18 and KIM-1 were elevated in
ICU patients with pre-renal AKI compared to those with-
out AKI, but were lower than values for patients whose
AKI did not resolve within 48 hrs [27]. An important lim-
itation of our study is that it was a relatively small retro-
spective biomarker qualification study with 45 subjects.
Larger studies will be needed to confirm the prognostic
ability of angiotensinogen in this population.
In this study we also used the maximum LR+ and
minimum LR- to define cutoffs at which patients could
be stratified into high risk and low risk groups for each
outcome, and showed that using these cutoffs, the risk
of a significant percentage of the cohort could be
assigned with a high level of confidence. We evaluated
multiple cutoff values since the purpose of a biomarker
affects the threshold that will be used. This approach
could be particularly useful for screening patients for
enrollment into a clinical trial to enrich the study popu-
lation with patients who will meet the outcome. For
instance, a study to test the efficacy of early initiation of
RRT could use as an inclusion criterion a uAnCR value
> 230 ng/mg. Using this cutoff we identified 43.5% of
the patients who would require RRT or die, while
excluding 95.5% of patients who would not meet the
endpoint. Therefore, if a target enrollment of 500 is
assumed, we would only enroll 45 patients who would
not meet the endpoint RRT or death, and who would
gain no survival benefit from the intervention. However,
using this cutoff we need to screen a total of 2,083
patients to meet the target enrollment. Of the 1,583
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Figure 4 Urinary angiotensinogen-to-creatinine ratio in pre-
renal acute kidney injury (AKI) compared to AKI of other
etiologies. The box and whiskers plots show the median and
interquartile range. Error bars represent the 5th and 95th percentiles.
Groups were compared with the Mann-Whitney U-test. UAnCR,
angiotensinogen-to-creatinine ratio.
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meet the endpoint, and so the benefit of enrichment
would need to be weighed against the cost of screening.
Our findings could also have important implications
for our understanding of the pathobiology of AKI.
Angiotensinogen is the principal substrate of renin, and
a major driver of activation of the renin-angiotensin sys-
tem (RAS). Animal studies have suggested a role for the
RAS in the molecular mechanisms of AKI. It has been
observed that angiotensin II increases and angiotensin
1-7, the molecular counterbalance of angiotensin II
decreases in kidney tissue following ischemia reperfusion
injury in rats [28,29]. Angiotensin II can contribute to
renal injury through pro-inflammatory effects mediated
by the nuclear factor-B (NF-B) pathway, and it has
been demonstrated that inhibition of angiotensin con-
verting enzyme and the angiotensin II type 1 receptor with
captopril and losartan, respectively, reduce renal inflam-
mation and mitigate the severity of AKI in rats subjected
to renal ischemia reperfusion injury [30,31]. Interestingly,
intrarenal angiotensin II concentration strongly correlates
with urinary angiotensinogen concentration (r = 0.79), but
is not correlated with plasma angiotensinogen [32]. Our
findings are suggestive of a role of the RAS in modulating
the severity of AKI, a notion which is supported by a
recent study in which an association was reported between
severity of tubular atrophy and urinary angiotensinogen
among individuals with chronic kidney disease [33].
Conclusions
Urinary AnCR could be useful as a prognostic AKI bio-
marker in the setting of the ICU. It could be used to evalu-
ate a patient’s risk of adverse outcomes, potentially leading
to an altered interventional strategy or improved enroll-
ment in clinical trials. Angiotensinogen also appears to
discriminate between AKI of pre-renal etiology and other
etiologies and may be useful to discriminate between
patients with pre-renal azotemia and intrinsic renal injury.
Key messages
• Urinary angiotensinogen could be used as a prog-
nostic biomarker of AKI in the ICU.
• Urinary angiotensinogen predicts adverse outcomes
in patients with AKI and could be used in clinical
trial design to enrich the study population with
patients who might benefit from intervention.
• Urinary angiotensinogen has the potential to be
useful in the discrimination of pre-renal AKI from
intrinsic AKI.
• Urinary angiotensinogen concentrations could
reflect activation of the intrarenal RAS during AKI.
Additional material
Additional file 1: Urinary angiotensinogen/creatinine ratio (uAnCR)
by acute kidney injury (AKI) etiology. Patients who developed AKI in
the ICU were grouped by the etiology underlying the AKI. The median
(black dot) and interquartile range (error bars) are shown. The * symbol
indicates a statistically significant difference when compared to the pre-
renal group in post hoc pairwise comparison (P < 0.05).
Abbreviations
AKI: acute kidney injury; AKIN: Acute Kidney Injury Network; AUC; area under
the curve of a receiver operator characteristics curve; ELISA: enzyme-linked
immunosorbent assay; FENa: fractional excretion of sodium; FEUrea:
fractional excretion of urea; GFR: glomerular filtration rate; IL-18: interleukin
18; IQR: interquartile range; KDIGO: Kidney Disease: Improving Global
Outcomes; KIM-1: kidney injury molecule 1; LOS: length of stay; LR+: positive
likelihood ratio; LR-: negative likelihood ratio; MUSC: Medical University of
South Carolina; NF-kB: nuclear factor -kB; NGAL: neutrophil gelatinase
associated lipocalin; OR: odds ratio; RAS: renin angiotensin system; RIFLE: risk,
injury, failure, loss, end-stage renal failure; ROC: receiver operator
characteristics; RRT: renal replacement therapy; sCr: serum creatinine; uAnCR:
urinary angiotensinogen to creatinine ratio.
Table 2 Summary of performance characteristics of urinary angiotensinogen as a predictor of outcomes among acute
kidney injury patients
Outcome AUCa Cutoff (ng/mg) Sensitivity Specificity
RRT or deathb 0.73
(0.58 to 0.88)
Best: > 34.76 78.3% 54.6%
Max LR+: > 230.0 43.5% 95.5%
Min LR-: ≤ 7.58 95.7% 31.8%
LOSc 0.77
(0.63 to 0.92)
Best: > 59.61 60.6% 83.3%
Max LR+: > 123.5 43.5% 95.5%
Min LR-: ≤ 3.31 97.1% 25.0%
Worsening AKId 0.77
(0.63 to 0.91)
Best: > 34.76 87.0% 63.6%
Max LR+: > 230.0 39.1% 90.9%
Min LR-: ≤ 21.24 95.7% 59.1%
aAUC, area under the receiver operator characteristic curve; bRRT, renal replacement therapy; cLOS, length of hospital stay (days after sample collection);
dworsening acute kidney injury (AKI) defined as an increase in serum creatinine > 0.3 mg/dL after sample collection or initiation of RRT; LR, likelihood ratio; Max,
maximum; Min, minimum.
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